EBS - Novavax taps Polish biotech firm Mabion for COVID-19 vaccine production

Mabion, a Polish biotechnology company has partnered with Novavax (NVAX) in a framework agreement that will pave the way for a potential manufacturing contract with the U.S.-based company for its COVID-19 vaccine candidate.Per the terms of the agreement, Mabion will initiate the production of technical batches of antigen for NVXCoV2373, Novavax’ COVID-19 vaccine candidate.Subject to the successful production of the technical batches, and regulatory approval for NVXCoV2373, the companies will extend the partnership into a broader contract to commercially produce the antigen for the vaccine.The initial steps to demonstrate feasibility will be conducted during 1H 2021.Amid supply constraints to vaccine production, Novavax fell ~14.3% yesterday along with contract manufacturers, Emergent Biosolutions (EBS) -2.8% and Catalent (CTLT) -2.3% which acquired manufacturing assets from Novavx in 2019.

For further details see:

Novavax taps Polish biotech firm Mabion for COVID-19 vaccine production